<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Netherton syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Netherton syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Netherton syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0009735" target="_blank">
                        MONDO:0009735
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">inherited ichthyosis</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">genodermatosis</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Netherton syndrome is a rare autosomal recessive inherited ichthyosis caused by SPINK5 loss-of-function variants, with resulting LEKTI deficiency, epidermal barrier dysfunction, chronic skin inflammation, and prominent atopic features.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <a class="stat-link" href="#inheritance">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Inheritance</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#datasets">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Datasets</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#trials">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Trials</div>
            </div>
            </a>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">skin disorder</span>
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        
        <div class="card" id="inheritance">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #92400e;">üë™</div>
                <h2 class="card-title">Inheritance</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal recessive inheritance
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000007" target="_blank">
                            HP:0000007
                        </a>
                    </span>
                    
                </div>
                
                
    
    
    <div class="item-meta">
        
        <span class="tag tag-classification">
            Autosomal recessive inheritance
        </span>
        
        
        
        
        
    </div>
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27905021" target="_blank">PMID:27905021</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system."</div>
                
                
                <div class="evidence-explanation">This review explicitly states the autosomal recessive inheritance mode for Netherton syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Ichthyosiform erythroderma-predominant Netherton syndrome
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Clinical subtype with persistent diffuse erythroderma and ichthyosiform scaling.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634098" target="_blank">PMID:38634098</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa."</div>
                
                
                <div class="evidence-explanation">This supports ichthyosiform erythroderma as one recognized clinical subtype of NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Ichthyosis linearis circumflexa-predominant Netherton syndrome
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Clinical subtype characterized by migratory polycyclic erythematous plaques with characteristic double-edged scale.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634098" target="_blank">PMID:38634098</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa."</div>
                
                
                <div class="evidence-explanation">This supports ichthyosis linearis circumflexa as a second recognized clinical subtype of NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">SPINK5 loss-of-function variants</div>
                
                <div class="item-desc">Biallelic pathogenic SPINK5 variants reduce functional SPINK5 output and initiate Netherton syndrome pathogenesis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        keratinocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        SPINK5
                        
                        <a href="https://bioregistry.io/hgnc:15464" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        skin epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001003" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"AbstractNetherton syndrome (NS) is a rare skin disease caused by loss-of-function mutations in the serine peptidase inhibitor Kazal type 5 (SPINK5) gene."</div>
                
                
                <div class="evidence-explanation">This supports SPINK5 loss of function as the initiating lesion in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40607310" target="_blank">PMID:40607310</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, leading to impaired skin barrier function and immune dysregulation."</div>
                
                
                <div class="evidence-explanation">This supports pathogenic SPINK5 variants as the primary molecular driver in human NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">LEKTI protein deficiency</div>
                
                <div class="item-desc">Reduced or absent LEKTI removes a key epidermal serine-protease brake in skin and hair-bearing epithelium.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        keratinocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        skin epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001003" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI."</div>
                
                
                <div class="evidence-explanation">This supports LEKTI deficiency as a distinct downstream molecular consequence of SPINK5 defects.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Unchecked epidermal kallikrein protease activity</div>
                
                <div class="item-desc">Loss of LEKTI control leads to increased epidermal protease activity, including KLK-dependent proteolysis in the stratum corneum.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        keratinocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        proteolysis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006508" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        stratum corneum of epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002027" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."</div>
                
                
                <div class="evidence-explanation">This supports increased protease activity as a central intermediary event in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines."</div>
                
                
                <div class="evidence-explanation">This directly supports KLK-driven IL-36 cytokine processing.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Corneodesmosome degradation and accelerated desquamation</div>
                
                <div class="item-desc">Excess serine-protease activity accelerates stratum corneum protein breakdown, causing premature shedding and unstable cornified layers.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        proteolysis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006508" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        keratinization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0031424" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        stratum corneum of epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002027" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."</div>
                
                
                <div class="evidence-explanation">This supports protease-driven barrier/cornification pathology in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epidermal barrier breakdown and increased transepidermal water loss</div>
                
                <div class="item-desc">Defective stratum corneum integrity increases permeability to water, allergens, and microbes, establishing chronic barrier failure.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        keratinocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        keratinization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0031424" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        skin epidermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001003" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."</div>
                
                
                <div class="evidence-explanation">This supports barrier dysfunction as a key pathophysiologic hub in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38025195" target="_blank">PMID:38025195</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Loss of LEKTI induces severe skin barrier defect."</div>
                
                
                <div class="evidence-explanation">This provides additional human case-level support for severe barrier disruption in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">KLK-mediated IL-36 cytokine processing</div>
                
                <div class="item-desc">KLK proteases cleave IL-36 cytokine precursors, amplifying epidermal pro-inflammatory signaling.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines."</div>
                
                
                <div class="evidence-explanation">This defines the KLK-to-IL-36 activation step in the NS inflammatory cascade.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/dermatopathology11030024" target="_blank">DOI:10.3390/dermatopathology11030024</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both cases demonstrated robust expression of IL-36."</div>
                
                
                <div class="evidence-explanation">This supports IL-36 pathway activation in NS patient skin biopsies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Enhanced cutaneous entry of allergens and microbes</div>
                
                <div class="item-desc">Persistent barrier failure promotes antigen penetration and microbial exposure, increasing both atopic sensitization and infection vulnerability.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/41126693" target="_blank">PMID:41126693</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."</div>
                
                
                <div class="evidence-explanation">This supports concurrent allergy-prone and infection-prone consequences of barrier failure.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">IL-17/IL-36 inflammatory amplification</div>
                
                <div class="item-desc">Combined IL-36 and IL-17 pathway activation sustains epidermal inflammation and drives persistent erythro-inflammatory and eczematous disease.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        interleukin-17-mediated signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0097400" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."</div>
                
                
                <div class="evidence-explanation">This supports IL-17/IL-36 axis overactivation as a core inflammatory driver in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/dermatopathology11030024" target="_blank">DOI:10.3390/dermatopathology11030024</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both cases demonstrated robust expression of IL-36."</div>
                
                
                <div class="evidence-explanation">This provides patient-level biopsy support for IL-36-driven inflammation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hair shaft structural fragility from follicular protease imbalance</div>
                
                <div class="item-desc">SPINK5/LEKTI dysfunction in hair-bearing epithelium contributes to defective hair-shaft integrity, including trichorrhexis invaginata susceptibility.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        keratinocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        SPINK5
                        
                        <a href="https://bioregistry.io/hgnc:15464" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        keratinization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0031424" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."</div>
                
                
                <div class="evidence-explanation">This supports hair-shaft defects as a direct disease consequence within the SPINK5/LEKTI mechanism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Corneodesmosome_degradation_and_accelerated_desquamation[&#34;Corneodesmosome degradation and accelerated desquamation&#34;]
    Ichthyosis[&#34;Ichthyosis&#34;]
    Recurrent_infections[&#34;Recurrent infections&#34;]
    Hair_shaft_abnormality[&#34;Hair shaft abnormality&#34;]
    Unchecked_epidermal_kallikrein_protease_activity[&#34;Unchecked epidermal kallikrein protease activity&#34;]
    Erythroderma[&#34;Erythroderma&#34;]
    LEKTI_protein_deficiency[&#34;LEKTI protein deficiency&#34;]
    KLK_mediated_IL_36_cytokine_processing[&#34;KLK-mediated IL-36 cytokine processing&#34;]
    Atopic_dermatitis[&#34;Atopic dermatitis&#34;]
    Hair_shaft_structural_fragility_from_follicular_protease_imbalance[&#34;Hair shaft structural fragility from follicular protease imbalance&#34;]
    Epidermal_barrier_breakdown_and_increased_transepidermal_water_loss[&#34;Epidermal barrier breakdown and increased transepidermal water loss&#34;]
    IL_17_IL_36_inflammatory_amplification[&#34;IL-17/IL-36 inflammatory amplification&#34;]
    SPINK5_loss_of_function_variants[&#34;SPINK5 loss-of-function variants&#34;]
    Pruritus[&#34;Pruritus&#34;]
    Failure_to_thrive[&#34;Failure to thrive&#34;]
    Enhanced_cutaneous_entry_of_allergens_and_microbes[&#34;Enhanced cutaneous entry of allergens and microbes&#34;]

    SPINK5_loss_of_function_variants --&gt; LEKTI_protein_deficiency
    LEKTI_protein_deficiency --&gt; Unchecked_epidermal_kallikrein_protease_activity
    LEKTI_protein_deficiency --&gt; Hair_shaft_structural_fragility_from_follicular_protease_imbalance
    Unchecked_epidermal_kallikrein_protease_activity --&gt; Corneodesmosome_degradation_and_accelerated_desquamation
    Unchecked_epidermal_kallikrein_protease_activity --&gt; KLK_mediated_IL_36_cytokine_processing
    Corneodesmosome_degradation_and_accelerated_desquamation --&gt; Epidermal_barrier_breakdown_and_increased_transepidermal_water_loss
    Corneodesmosome_degradation_and_accelerated_desquamation --&gt; Ichthyosis
    Epidermal_barrier_breakdown_and_increased_transepidermal_water_loss --&gt; Enhanced_cutaneous_entry_of_allergens_and_microbes
    Epidermal_barrier_breakdown_and_increased_transepidermal_water_loss --&gt; Recurrent_infections
    Epidermal_barrier_breakdown_and_increased_transepidermal_water_loss --&gt; Pruritus
    KLK_mediated_IL_36_cytokine_processing --&gt; IL_17_IL_36_inflammatory_amplification
    Enhanced_cutaneous_entry_of_allergens_and_microbes --&gt; IL_17_IL_36_inflammatory_amplification
    Enhanced_cutaneous_entry_of_allergens_and_microbes --&gt; Atopic_dermatitis
    Enhanced_cutaneous_entry_of_allergens_and_microbes --&gt; Recurrent_infections
    IL_17_IL_36_inflammatory_amplification --&gt; Erythroderma
    IL_17_IL_36_inflammatory_amplification --&gt; Atopic_dermatitis
    IL_17_IL_36_inflammatory_amplification --&gt; Pruritus
    IL_17_IL_36_inflammatory_amplification --&gt; Failure_to_thrive
    Hair_shaft_structural_fragility_from_follicular_protease_imbalance --&gt; Hair_shaft_abnormality

    style Corneodesmosome_degradation_and_accelerated_desquamation fill:#dbeafe
    style Ichthyosis fill:#fef3c7
    style Recurrent_infections fill:#fef3c7
    style Hair_shaft_abnormality fill:#fef3c7
    style Unchecked_epidermal_kallikrein_protease_activity fill:#dbeafe
    style Erythroderma fill:#fef3c7
    style LEKTI_protein_deficiency fill:#dbeafe
    style KLK_mediated_IL_36_cytokine_processing fill:#dbeafe
    style Atopic_dermatitis fill:#fef3c7
    style Hair_shaft_structural_fragility_from_follicular_protease_imbalance fill:#dbeafe
    style Epidermal_barrier_breakdown_and_increased_transepidermal_water_loss fill:#dbeafe
    style IL_17_IL_36_inflammatory_amplification fill:#dbeafe
    style SPINK5_loss_of_function_variants fill:#dbeafe
    style Pruritus fill:#fef3c7
    style Failure_to_thrive fill:#fef3c7
    style Enhanced_cutaneous_entry_of_allergens_and_microbes fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Immune<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Integument<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Growth<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Immune
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Recurrent infections
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002719" target="_blank">
                                Recurrent infections
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002719)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/41126693" target="_blank">PMID:41126693</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."</div>
                
                
                <div class="evidence-explanation">This supports recurrent infection susceptibility as part of the NS phenotype spectrum.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40607310" target="_blank">PMID:40607310</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions."</div>
                
                
                <div class="evidence-explanation">This provides direct case-level evidence for recurrent severe infections in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Ichthyosis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0008064" target="_blank">
                                Ichthyosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0008064)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."</div>
                
                
                <div class="evidence-explanation">This directly supports ichthyosis as a core clinical manifestation of NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pruritus
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000989" target="_blank">
                                Pruritus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000989)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT04244006" target="_blank">clinicaltrials:NCT04244006</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus."</div>
                
                
                <div class="evidence-explanation">Trial summary explicitly identifies pruritus as a persistent symptom and treatment target.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40607310" target="_blank">PMID:40607310</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"He demonstrated substantial clinical benefits, with marked relief from pruritus resulting in better quality of life."</div>
                
                
                <div class="evidence-explanation">This supports that pruritus is a major and treatment-responsive symptomatic burden in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Failure to thrive
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001508" target="_blank">
                                Failure to thrive
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001508)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39931731" target="_blank">PMID:39931731</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We observed that patients with variants or homozygous variants located in the 5&#39; half of the gene were more likely to experience failure to thrive (P &lt; 0.05)."</div>
                
                
                <div class="evidence-explanation">This supports genotype-associated risk of failure to thrive in NS cohorts.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634098" target="_blank">PMID:38634098</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We describe an 8-year-old boy with genetically proven NS treated with intravenous immunoglobulin for recurrent skin and systemic infections from infancy, growth retardation, and associated erythroderma."</div>
                
                
                <div class="evidence-explanation">This supports growth retardation/failure-to-thrive manifestations in pediatric NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Erythroderma
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001019" target="_blank">
                                Erythroderma
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001019)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/41126693" target="_blank">PMID:41126693</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."</div>
                
                
                <div class="evidence-explanation">This explicitly reports erythroderma as a characteristic phenotype in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40299794" target="_blank">PMID:40299794</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Physical examination showed generalized erythroderma and polycyclic and serpiginous erythematous plaques with double-edged scales at the margins."</div>
                
                
                <div class="evidence-explanation">This case report provides direct clinical evidence for erythroderma in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hair shaft abnormality
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003328" target="_blank">
                                Abnormal hairshaft morphology
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003328)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."</div>
                
                
                <div class="evidence-explanation">This supports hair-shaft abnormalities as a core component of the NS clinical triad.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40299794" target="_blank">PMID:40299794</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Trichoscopy of the scalp revealed a hair shaft abnormality, specifically trichorrhexis invaginata."</div>
                
                
                <div class="evidence-explanation">This provides direct clinical confirmation of characteristic bamboo-hair morphology in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Atopic dermatitis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001047" target="_blank">
                                Atopic dermatitis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001047)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene."</div>
                
                
                <div class="evidence-explanation">This supports atopic-dermatitis-like presentations and diagnostic overlap in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40299794" target="_blank">PMID:40299794</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The patient was previously diagnosed with atopic dermatitis and had been treated with systemic corticosteroids and omalizumab, without improvement."</div>
                
                
                <div class="evidence-explanation">This supports frequent diagnostic overlap and initial misclassification as severe atopic dermatitis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SPINK5
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI."</div>
                
                
                <div class="evidence-explanation">This directly supports SPINK5 as the causal gene and links genotype to LEKTI deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27905021" target="_blank">PMID:27905021</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The identification of SPINK5, which encodes for the serine protease inhibitor LEKTI, as the gene responsible for Netherton syndrome, enabled the search for causative mutations in Netherton syndrome patients and families."</div>
                
                
                <div class="evidence-explanation">This supports SPINK5 as the established disease gene and highlights genotype-phenotype analysis in affected families.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39931731" target="_blank">PMID:39931731</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Among 162 patients, we identified 324 allele variants, comprising 75 different mutations."</div>
                
                
                <div class="evidence-explanation">This supports broad allelic heterogeneity and the need for comprehensive SPINK5 variant interpretation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive topical skin care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Emollients and topical anti-inflammatory therapy remain baseline management for scaling and eczematous inflammation, though control is often incomplete.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT04244006" target="_blank">clinicaltrials:NCT04244006</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus."</div>
                
                
                <div class="evidence-explanation">This trial summary supports current reliance on topical supportive care and its limitations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ex vivo SPINK5 gene-corrected epidermal sheet grafting (investigational)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001001" target="_blank">
                            MAXO:0001001
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Phase I ex vivo lentiviral gene therapy strategy using autologous epidermal sheets generated from genetically modified skin stem cells to restore LEKTI in Netherton syndrome.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01545323" target="_blank">clinicaltrials:NCT01545323</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells."</div>
                
                
                <div class="evidence-explanation">This supports an ex vivo lentiviral SPINK5 gene-correction strategy in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01545323" target="_blank">clinicaltrials:NCT01545323</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome."</div>
                
                
                <div class="evidence-explanation">This supports autologous epidermal sheet grafting from genetically corrected skin stem cells as the investigational treatment approach.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cytokine-targeted systemic pharmacotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        dupilumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C162455" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        secukinumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C152315" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        abrocitinib
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C166985" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Biologics and JAK inhibitors are emerging options in severe disease, targeting IL-4/IL-13, IL-17, IL-36, and JAK pathways.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40888388" target="_blank">PMID:40888388</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This review provides a comprehensive overview of the current clinical landscape and future directions of biologics (e.g., dupilumab, secukinumab, ustekinumab) and small-molecule therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib) in the treatment of NS."</div>
                
                
                <div class="evidence-explanation">This supports use of cytokine-targeted and JAK-pathway therapies in severe NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40888388" target="_blank">PMID:40888388</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Though evidence remains limited to case reports and small series, preliminary data suggest that cytokine-targeted interventions-particularly those inhibiting IL-4, IL-13, IL-17, IL-36, and JAK pathways-may offer tangible clinical benefits."</div>
                
                
                <div class="evidence-explanation">This supports potential efficacy while acknowledging current evidence limits.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40969297" target="_blank">PMID:40969297</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both patients had swift and enduring enhancement of skin lesions during the follow-up period."</div>
                
                
                <div class="evidence-explanation">This case series adds contemporary human evidence that biologic pathway targeting can improve NS skin disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Immunoglobulin and biologic systemic therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        immunoglobulin
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C572" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        dupilumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C162455" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        secukinumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C152315" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Systematic review data indicate skin improvement in many reported cases with immunoglobulins and biologics.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35464459" target="_blank">PMID:35464459</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Immunoglobulins (13/15 cases) and biologicals (18/21 cases) showed improvement of the skin."</div>
                
                
                <div class="evidence-explanation">This supports observed skin benefit in aggregated case-based treatment evidence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634098" target="_blank">PMID:38634098</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Under this therapy, his skin status, infectious exacerbations, and quality of life all improved."</div>
                
                
                <div class="evidence-explanation">This provides additional pediatric case-level support for IVIG-centered systemic therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intravenous immunoglobulin (IVIG) for infection-prone pediatric NS
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        immunoglobulin
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C572" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">High-dose IVIG has been used in children with recurrent skin/systemic infections and severe inflammatory skin disease, with reported improvement in skin status and infectious exacerbations.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634098" target="_blank">PMID:38634098</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"KEY CLINICAL MESSAGE: High-dose intravenous immunoglobulin exhibits great potential in the treatment of Netherton syndrome."</div>
                
                
                <div class="evidence-explanation">This explicitly supports IVIG as a promising strategy in pediatric NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40607310" target="_blank">PMID:40607310</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions."</div>
                
                
                <div class="evidence-explanation">This supports IVIG use in infection-prone NS with severe recurrent admissions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Dupilumab (IL-4/IL-13 pathway inhibition)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        dupilumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C162455" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dupilumab has shown improvement in pruritus and inflammatory skin disease in pediatric and mixed-age NS case reports/series.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40607310" target="_blank">PMID:40607310</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"When he was 6 years old, dupilumab was added to reduce skin inflammation and improve skin barrier function before food reintroduction."</div>
                
                
                <div class="evidence-explanation">This supports dupilumab targeting inflammatory and barrier manifestations in pediatric NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40969297" target="_blank">PMID:40969297</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab."</div>
                
                
                <div class="evidence-explanation">This supports real-world use of dupilumab across pediatric and young-adult NS cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35327681" target="_blank">PMID:35327681</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash."</div>
                
                
                <div class="evidence-explanation">This adds additional case-level evidence for dupilumab benefit on pruritus and inflammatory skin burden.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Secukinumab (IL-17 pathway inhibition)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        secukinumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C152315" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">IL-17A blockade with secukinumab has shown clinical improvement in refractory NS in case-level evidence.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40299794" target="_blank">PMID:40299794</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"After 2 injections, the patient&#39;s condition markedly improved and the effect after the last injection was maintained for 4-5 months."</div>
                
                
                <div class="evidence-explanation">This supports clinically meaningful short-term and sustained response to secukinumab in refractory NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40969297" target="_blank">PMID:40969297</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab."</div>
                
                
                <div class="evidence-explanation">This supports secukinumab use as part of targeted biologic treatment strategies in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Abrocitinib (JAK1 inhibitor)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        abrocitinib
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C166985" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">JAK1 inhibition with abrocitinib has shown symptomatic and severity improvements in case-level NS evidence.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40159127" target="_blank">PMID:40159127</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity."</div>
                
                
                <div class="evidence-explanation">This supports JAK1 inhibition as a promising targeted option in NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Secukinumab and dupilumab combination (investigational/observational)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        secukinumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C152315" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        dupilumab
                        
                        <a href="http://purl.obolibrary.org/obo/NCIT_C162455" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Combination IL-17A and IL-4/IL-13 blockade has been reported in severe pediatric NS cohorts.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT07151508" target="_blank">clinicaltrials:NCT07151508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome."</div>
                
                
                <div class="evidence-explanation">This supports real-world investigational use of combination biologic therapy in severe pediatric NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Total serum IgE
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Atopic/inflammatory Netherton syndrome is frequently associated with elevated total IgE, including markedly high baseline values in case-level reports.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40299794" target="_blank">PMID:40299794</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The blood tests demonstrated elevated IgE levels."</div>
                
                
                <div class="evidence-explanation">This directly supports elevated IgE as a biochemical feature in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40607310" target="_blank">PMID:40607310</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Serologically, total his serum IgE levels decreased from 1078 IU/mL to 55.8 IU/mL following dupilumab therapy."</div>
                
                
                <div class="evidence-explanation">This supports high baseline IgE in NS and demonstrates dynamic change with targeted therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38406644" target="_blank">PMID:38406644</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The patient has atopic diathesis, recurrent skin infections, increased levels of IgE, and delayed physical development."</div>
                
                
                <div class="evidence-explanation">This supports increased IgE as a recurrent biochemical feature in severe NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    IL-17/IL-36 inflammatory axis activity
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Inflammatory pathway activation is observed in both skin and blood and contributes to persistent erythro-inflammatory disease activity.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40888388" target="_blank">PMID:40888388</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"NS patients commonly show activation of the inflammatory axis, centered on IL-17 and IL-36, in the skin and blood, and show a psoriasis-like shift to Th17."</div>
                
                
                <div class="evidence-explanation">This supports IL-17/IL-36 pathway activation as a measurable biochemical-inflammatory signature in NS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank">DOI:10.1038/s42003-024-05780-y</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."</div>
                
                
                <div class="evidence-explanation">This supports conserved cytokine-axis upregulation across NS patients and mechanistic model systems.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">üîÄ</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">5</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Netherton syndrome:
            </p>
            
            
            
            <div class="item-box differential-box">
                <div class="item-name">
                    
                    <a class="item-name-link" href="Atopic_Dermatitis.html">Atopic eczema</a>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0004980" target="_blank">
                            MONDO:0004980
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Severe atopic eczema can clinically overlap with NS, especially early in life with eczematous inflammation and pruritus.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Hair shaft abnormalities and inherited ichthyosis features support Netherton syndrome over isolated atopic eczema.</li>
                        
                        <li>Pathogenic SPINK5 variants and LEKTI pathway dysfunction support Netherton syndrome.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/genes14051080" target="_blank">DOI:10.3390/genes14051080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene."</div>
                
                
                <div class="evidence-explanation">This provides direct evidence of diagnostic confusion between NS and severe atopic dermatitis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38601387" target="_blank">PMID:38601387</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"While eczema was included in our differential diagnoses, the patient&#39;s systemic symptoms, including failure to thrive, prompted our team to consider other diagnoses."</div>
                
                
                <div class="evidence-explanation">This supports practical diagnostic overlap with eczema and the need to broaden differential assessment in severe infantile disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            
            
            <div class="item-box differential-box">
                <div class="item-name">
                    
                    <span class="missing-disease-name" title="No Dismech page yet for this disease">Autosomal recessive congenital ichthyosis</span>
                    <span class="curation-gap-badge">Not Yet Curated</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0017265" target="_blank" class="missing-ontology-link">
                            MONDO:0017265
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    NS belongs to inherited ichthyosis disorders and may overlap clinically with other autosomal recessive congenital ichthyosis subtypes.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Hair shaft abnormalities and strong atopic/allergic predisposition are characteristic clues favoring Netherton syndrome.</li>
                        
                        <li>SPINK5/LEKTI-associated protease dysregulation provides mechanistic specificity for Netherton syndrome.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27905021" target="_blank">PMID:27905021</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system."</div>
                
                
                <div class="evidence-explanation">This supports overlap within ARCI-like ichthyosis presentations while defining NS as a specific syndromic form.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            
            
            <div class="item-box differential-box">
                <div class="item-name">
                    
                    <span class="missing-disease-name" title="No Dismech page yet for this disease">Chanarin-Dorfman syndrome</span>
                    <span class="curation-gap-badge">Not Yet Curated</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0010155" target="_blank" class="missing-ontology-link">
                            MONDO:0010155
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Chanarin-Dorfman syndrome can overlap with syndromic ichthyosis presentations and requires molecular discrimination from Netherton syndrome.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Trichorrhexis invaginata with pathogenic SPINK5 variants supports Netherton syndrome over alternative syndromic ichthyoses.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40709761" target="_blank">PMID:40709761</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Additionally, 4 patients were diagnosed with syndromic ichthyosis, comprising 1 case of Chanarin-Dorfman syndrome and 3 cases of Netherton syndrome."</div>
                
                
                <div class="evidence-explanation">This supports real-world diagnostic overlap between NS and Chanarin-Dorfman syndrome in inherited ichthyosis cohorts.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            
            
            <div class="item-box differential-box">
                <div class="item-name">
                    
                    <a class="item-name-link" href="Psoriasis.html">Psoriasis</a>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005083" target="_blank">
                            MONDO:0005083
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Chronic erythro-scaling inflammatory dermatoses such as psoriasis can mimic Netherton syndrome and delay diagnosis.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Hair shaft abnormalities with congenital onset and syndromic ichthyosis features support Netherton syndrome over psoriasis-spectrum diseases.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38638763" target="_blank">PMID:38638763</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits."</div>
                
                
                <div class="evidence-explanation">This directly supports real-world diagnostic confusion between NS and psoriasis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            
            
            <div class="item-box differential-box">
                <div class="item-name">
                    
                    <span class="missing-disease-name" title="No Dismech page yet for this disease">Pityriasis rubra pilaris</span>
                    <span class="curation-gap-badge">Not Yet Curated</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0100017" target="_blank" class="missing-ontology-link">
                            MONDO:0100017
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Pityriasis rubra pilaris can present with erythroderma and scaling that overlap with Netherton syndrome.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Hair shaft abnormalities and congenital ichthyosis features support Netherton syndrome over pityriasis rubra pilaris.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38638763" target="_blank">PMID:38638763</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits."</div>
                
                
                <div class="evidence-explanation">This directly supports real-world diagnostic confusion between NS and pityriasis rubra pilaris.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        
        <div class="card" id="datasets">
            <div class="card-header">
                <div class="card-icon" style="background: #e0f2fe; color: #0284c7;">üìä</div>
                <h2 class="card-title">Related Datasets</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    Transcriptome profiling of lesional skin from Spink5 conditional knock-out mice
                    
                    <span class="dataset-accession">
                        <a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224280" target="_blank">geo:GSE224280</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">GEO transcriptome dataset from lesional skin in a viable Spink5 conditional knock-out Netherton syndrome mouse model.</div>
                
                <div class="item-meta">
                    
                    
                    <span class="tag tag-datatype">BULK RNA SEQ</span>
                    
                    
                    
                </div>
                
                
                
                
    
    
                
                <div style="margin-top: 8px; font-size: 0.85rem;">
                    <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank" style="color: var(--secondary);">DOI:10.1038/s42003-024-05780-y</a>
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/GEO:GSE224280" target="_blank">GEO:GSE224280</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"To characterize this model at the molecular level, we induced Spink5 deletion in young adult mice and collected lesional skin samples for transcriptome analyses."</div>
                
                
                <div class="evidence-explanation">This supports transcriptomic dataset use for mechanistic profiling of Spink5-deficient skin.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    Transcriptome profiling of lymph nodes from Spink5 conditional knock-out mice
                    
                    <span class="dataset-accession">
                        <a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224409" target="_blank">geo:GSE224409</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">GEO transcriptome dataset from inguinal lymph nodes in the Spink5 conditional knock-out model to characterize systemic inflammation.</div>
                
                <div class="item-meta">
                    
                    
                    <span class="tag tag-datatype">BULK RNA SEQ</span>
                    
                    
                    
                </div>
                
                
                
                
    
    
                
                <div style="margin-top: 8px; font-size: 0.85rem;">
                    <a href="https://bioregistry.io/DOI:10.1038/s42003-024-05780-y" target="_blank" style="color: var(--secondary);">DOI:10.1038/s42003-024-05780-y</a>
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/GEO:GSE224409" target="_blank">GEO:GSE224409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"To study the systemic inflammation phenotype of this mouse model at the molecular level, we induced Spink5 deletion in the skin of young adult mice and collected inguinal lymph nodes for transcriptome analyses."</div>
                
                
                <div class="evidence-explanation">This supports transcriptomic profiling of lymphoid tissue to characterize systemic inflammatory mechanisms in NS models.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Clinical Trials -->
        
        <div class="card" id="trials">
            <div class="card-header">
                <div class="card-icon" style="background: #f5f3ff; color: #a855f7;">üî¨</div>
                <h2 class="card-title">Clinical Trials</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT01545323
                    
                    <span class="tag tag-phase">PHASE_I</span>
                    
                    
                    <span class="tag tag-status">UNKNOWN</span>
                    
                </div>
                
                <div class="item-desc">Phase I ex vivo lentiviral gene therapy trial evaluating autologous epidermal sheets generated from SPINK5-corrected skin stem cells in Netherton syndrome.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Ichthyosis
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0008064" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Erythroderma
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0001019" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01545323" target="_blank">clinicaltrials:NCT01545323</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The investigators have been developing a gene therapy approach to treat this disorder."</div>
                
                
                <div class="evidence-explanation">This supports clinical investigation of a gene therapy approach for Netherton syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01545323" target="_blank">clinicaltrials:NCT01545323</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome."</div>
                
                
                <div class="evidence-explanation">This describes the autologous SPINK5-corrected epidermal sheet intervention evaluated in the study.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT04244006
                    
                    <span class="tag tag-phase">PHASE_II</span>
                    
                    
                    <span class="tag tag-status">UNKNOWN</span>
                    
                </div>
                
                <div class="item-desc">Registered as a phase 2/3 pilot randomized placebo-controlled trial of dupilumab for moderate-to-severe Netherton syndrome.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Pruritus
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0000989" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Erythroderma
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0001019" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT04244006" target="_blank">clinicaltrials:NCT04244006</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The expected consequences of this study are that a 16-week course of dupilumab will be more effective than placebo for the treatment of moderate to severe NS Dupilumab could therefore improve skin condition and quality of life."</div>
                
                
                <div class="evidence-explanation">This supports ongoing/registered evaluation of dupilumab for clinically significant NS disease burden.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT07151508
                    
                    <span class="tag tag-phase">NOT_APPLICABLE</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">Completed observational study describing combination secukinumab and dupilumab use in severe pediatric Netherton syndrome.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Atopic dermatitis
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0001047" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT07151508" target="_blank">clinicaltrials:NCT07151508</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome."</div>
                
                
                <div class="evidence-explanation">This supports real-world evidence generation for combination biologic therapy in pediatric NS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Netherton syndrome
creation_date: &#34;2026-02-20T00:00:43Z&#34;
updated_date: &#34;2026-02-21T15:39:12Z&#34;
category: Mendelian
description: &gt;-
  Netherton syndrome is a rare autosomal recessive inherited ichthyosis caused
  by SPINK5 loss-of-function variants, with resulting LEKTI deficiency,
  epidermal barrier dysfunction, chronic skin inflammation, and prominent atopic
  features.
disease_term:
  preferred_term: Netherton syndrome
  term:
    id: MONDO:0009735
    label: Netherton syndrome
classifications:
  harrisons_chapter:
  - classification_value: skin disorder
  - classification_value: hereditary disease
parents:
- inherited ichthyosis
- genodermatosis
synonyms:
- Comel-Netherton syndrome
- Netherton syndrome
has_subtypes:
- name: Ichthyosiform erythroderma-predominant Netherton syndrome
  description: &gt;-
    Clinical subtype with persistent diffuse erythroderma and ichthyosiform
    scaling.
  evidence:
  - reference: PMID:38634098
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa.&#34;
    explanation: This supports ichthyosiform erythroderma as one recognized clinical subtype of NS.
- name: Ichthyosis linearis circumflexa-predominant Netherton syndrome
  description: &gt;-
    Clinical subtype characterized by migratory polycyclic erythematous plaques
    with characteristic double-edged scale.
  evidence:
  - reference: PMID:38634098
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa.&#34;
    explanation: This supports ichthyosis linearis circumflexa as a second recognized clinical subtype of NS.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:27905021
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system.&#34;
    explanation: This review explicitly states the autosomal recessive inheritance mode for Netherton syndrome.
pathophysiology:
- name: SPINK5 loss-of-function variants
  description: &gt;-
    Biallelic pathogenic SPINK5 variants reduce functional SPINK5 output and
    initiate Netherton syndrome pathogenesis.
  genes:
  - preferred_term: SPINK5
    term:
      id: hgnc:15464
      label: SPINK5
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: LEKTI protein deficiency
    description: SPINK5 loss of function reduces or abolishes LEKTI protein levels.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;AbstractNetherton syndrome (NS) is a rare skin disease caused by loss-of-function mutations in the serine peptidase inhibitor Kazal type 5 (SPINK5) gene.&#34;
    explanation: This supports SPINK5 loss of function as the initiating lesion in NS.
  - reference: PMID:40607310
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, leading to impaired skin barrier function and immune dysregulation.&#34;
    explanation: This supports pathogenic SPINK5 variants as the primary molecular driver in human NS.
- name: LEKTI protein deficiency
  description: &gt;-
    Reduced or absent LEKTI removes a key epidermal serine-protease brake in
    skin and hair-bearing epithelium.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: Unchecked epidermal kallikrein protease activity
    description: LEKTI deficiency permits excessive epidermal serine protease activity.
  - target: Hair shaft structural fragility from follicular protease imbalance
    description: LEKTI loss in hair follicles predisposes to bamboo-hair morphology.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI.&#34;
    explanation: This supports LEKTI deficiency as a distinct downstream molecular consequence of SPINK5 defects.
- name: Unchecked epidermal kallikrein protease activity
  description: &gt;-
    Loss of LEKTI control leads to increased epidermal protease activity,
    including KLK-dependent proteolysis in the stratum corneum.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  locations:
  - preferred_term: stratum corneum of epidermis
    term:
      id: UBERON:0002027
      label: stratum corneum of epidermis
  downstream:
  - target: Corneodesmosome degradation and accelerated desquamation
    description: Excessive proteolysis promotes premature corneocyte detachment.
  - target: KLK-mediated IL-36 cytokine processing
    description: KLKs proteolytically activate IL-36 family pro-cytokines.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling.&#34;
    explanation: This supports increased protease activity as a central intermediary event in NS.
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines.&#34;
    explanation: This directly supports KLK-driven IL-36 cytokine processing.
- name: Corneodesmosome degradation and accelerated desquamation
  description: &gt;-
    Excess serine-protease activity accelerates stratum corneum protein
    breakdown, causing premature shedding and unstable cornified layers.
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  - preferred_term: keratinization
    term:
      id: GO:0031424
      label: keratinization
  locations:
  - preferred_term: stratum corneum of epidermis
    term:
      id: UBERON:0002027
      label: stratum corneum of epidermis
  downstream:
  - target: Epidermal barrier breakdown and increased transepidermal water loss
    description: Corneocyte cohesion failure impairs the physical epidermal barrier.
  - target: Ichthyosis
    description: Disordered cornification and scaling manifest clinically as ichthyosis.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling.&#34;
    explanation: This supports protease-driven barrier/cornification pathology in NS.
- name: Epidermal barrier breakdown and increased transepidermal water loss
  description: &gt;-
    Defective stratum corneum integrity increases permeability to water, allergens,
    and microbes, establishing chronic barrier failure.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: keratinization
    term:
      id: GO:0031424
      label: keratinization
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: Enhanced cutaneous entry of allergens and microbes
    description: Increased permeability raises exposure to environmental antigens and pathogens.
  - target: Recurrent infections
    description: Barrier failure contributes to repeated skin and systemic infections.
  - target: Pruritus
    description: Barrier disruption drives itch through xerosis and neuroimmune activation.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling.&#34;
    explanation: This supports barrier dysfunction as a key pathophysiologic hub in NS.
  - reference: PMID:38025195
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Loss of LEKTI induces severe skin barrier defect.&#34;
    explanation: This provides additional human case-level support for severe barrier disruption in NS.
- name: KLK-mediated IL-36 cytokine processing
  description: &gt;-
    KLK proteases cleave IL-36 cytokine precursors, amplifying epidermal
    pro-inflammatory signaling.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: IL-17/IL-36 inflammatory amplification
    description: IL-36 signaling feeds forward into chronic inflammatory circuits.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines.&#34;
    explanation: This defines the KLK-to-IL-36 activation step in the NS inflammatory cascade.
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Both cases demonstrated robust expression of IL-36.&#34;
    explanation: This supports IL-36 pathway activation in NS patient skin biopsies.
- name: Enhanced cutaneous entry of allergens and microbes
  description: &gt;-
    Persistent barrier failure promotes antigen penetration and microbial exposure,
    increasing both atopic sensitization and infection vulnerability.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: IL-17/IL-36 inflammatory amplification
    description: Antigen and microbe exposure sustains chronic inflammatory signaling.
  - target: Atopic dermatitis
    description: Cutaneous allergen entry contributes to severe eczematous disease.
  - target: Recurrent infections
    description: Reduced barrier defense promotes repeated infectious episodes.
  evidence:
  - reference: PMID:41126693
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections.&#34;
    explanation: This supports concurrent allergy-prone and infection-prone consequences of barrier failure.
- name: IL-17/IL-36 inflammatory amplification
  description: &gt;-
    Combined IL-36 and IL-17 pathway activation sustains epidermal inflammation
    and drives persistent erythro-inflammatory and eczematous disease.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: interleukin-17-mediated signaling pathway
    term:
      id: GO:0097400
      label: interleukin-17-mediated signaling pathway
  downstream:
  - target: Erythroderma
    description: High inflammatory burden produces diffuse erythema and scaling.
  - target: Atopic dermatitis
    description: Chronic cytokine activation drives eczematous inflammation.
  - target: Pruritus
    description: Cytokine-mediated neuroimmune signaling contributes to severe itch.
  - target: Failure to thrive
    description: Sustained systemic inflammatory burden can impair growth in severe disease.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling.&#34;
    explanation: This supports IL-17/IL-36 axis overactivation as a core inflammatory driver in NS.
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Both cases demonstrated robust expression of IL-36.&#34;
    explanation: This provides patient-level biopsy support for IL-36-driven inflammation.
- name: Hair shaft structural fragility from follicular protease imbalance
  description: &gt;-
    SPINK5/LEKTI dysfunction in hair-bearing epithelium contributes to defective
    hair-shaft integrity, including trichorrhexis invaginata susceptibility.
  genes:
  - preferred_term: SPINK5
    term:
      id: hgnc:15464
      label: SPINK5
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: keratinization
    term:
      id: GO:0031424
      label: keratinization
  downstream:
  - target: Hair shaft abnormality
    description: Follicular structural defects manifest as bamboo hair and related shaft anomalies.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities.&#34;
    explanation: This supports hair-shaft defects as a direct disease consequence within the SPINK5/LEKTI mechanism.
phenotypes:
- name: Ichthyosis
  description: Generalized scaling disorder of cornification and barrier function.
  phenotype_term:
    preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities.&#34;
    explanation: This directly supports ichthyosis as a core clinical manifestation of NS.
- name: Erythroderma
  description: Diffuse inflammatory erythema with scaling involving large skin areas.
  phenotype_term:
    preferred_term: Erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: PMID:41126693
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections.&#34;
    explanation: This explicitly reports erythroderma as a characteristic phenotype in NS.
  - reference: PMID:40299794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Physical examination showed generalized erythroderma and polycyclic and serpiginous erythematous plaques with double-edged scales at the margins.&#34;
    explanation: This case report provides direct clinical evidence for erythroderma in NS.
- name: Hair shaft abnormality
  description: &gt;-
    Hair-shaft defects are characteristic in NS, often including
    trichorrhexis invaginata (bamboo hair).
  phenotype_term:
    preferred_term: Abnormal hairshaft morphology
    term:
      id: HP:0003328
      label: Abnormal hairshaft morphology
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities.&#34;
    explanation: This supports hair-shaft abnormalities as a core component of the NS clinical triad.
  - reference: PMID:40299794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Trichoscopy of the scalp revealed a hair shaft abnormality, specifically trichorrhexis invaginata.&#34;
    explanation: This provides direct clinical confirmation of characteristic bamboo-hair morphology in NS.
- name: Atopic dermatitis
  description: Eczematous inflammatory skin phenotype overlapping with atopic eczema.
  phenotype_term:
    preferred_term: Atopic dermatitis
    term:
      id: HP:0001047
      label: Atopic dermatitis
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene.&#34;
    explanation: This supports atopic-dermatitis-like presentations and diagnostic overlap in NS.
  - reference: PMID:40299794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The patient was previously diagnosed with atopic dermatitis and had been treated with systemic corticosteroids and omalizumab, without improvement.&#34;
    explanation: This supports frequent diagnostic overlap and initial misclassification as severe atopic dermatitis.
- name: Pruritus
  description: Chronic itch as a major symptomatic burden in NS.
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: clinicaltrials:NCT04244006
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus.&#34;
    explanation: Trial summary explicitly identifies pruritus as a persistent symptom and treatment target.
  - reference: PMID:40607310
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;He demonstrated substantial clinical benefits, with marked relief from pruritus resulting in better quality of life.&#34;
    explanation: This supports that pruritus is a major and treatment-responsive symptomatic burden in NS.
- name: Recurrent infections
  description: Increased susceptibility to recurrent infections associated with barrier dysfunction.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:41126693
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections.&#34;
    explanation: This supports recurrent infection susceptibility as part of the NS phenotype spectrum.
  - reference: PMID:40607310
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions.&#34;
    explanation: This provides direct case-level evidence for recurrent severe infections in NS.
- name: Failure to thrive
  description: Growth impairment in subsets of patients with severe or specific SPINK5 variant profiles.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:39931731
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We observed that patients with variants or homozygous variants located in the 5&#39; half of the gene were more likely to experience failure to thrive (P &lt; 0.05).&#34;
    explanation: This supports genotype-associated risk of failure to thrive in NS cohorts.
  - reference: PMID:38634098
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We describe an 8-year-old boy with genetically proven NS treated with intravenous immunoglobulin for recurrent skin and systemic infections from infancy, growth retardation, and associated erythroderma.&#34;
    explanation: This supports growth retardation/failure-to-thrive manifestations in pediatric NS.
biochemical:
- name: Total serum IgE
  presence: Elevated
  context: &gt;-
    Atopic/inflammatory Netherton syndrome is frequently associated with elevated
    total IgE, including markedly high baseline values in case-level reports.
  evidence:
  - reference: PMID:40299794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The blood tests demonstrated elevated IgE levels.&#34;
    explanation: This directly supports elevated IgE as a biochemical feature in NS.
  - reference: PMID:40607310
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Serologically, total his serum IgE levels decreased from 1078 IU/mL to 55.8 IU/mL following dupilumab therapy.&#34;
    explanation: This supports high baseline IgE in NS and demonstrates dynamic change with targeted therapy.
  - reference: PMID:38406644
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The patient has atopic diathesis, recurrent skin infections, increased levels of IgE, and delayed physical development.&#34;
    explanation: This supports increased IgE as a recurrent biochemical feature in severe NS.
- name: IL-17/IL-36 inflammatory axis activity
  presence: Elevated
  context: &gt;-
    Inflammatory pathway activation is observed in both skin and blood and
    contributes to persistent erythro-inflammatory disease activity.
  evidence:
  - reference: PMID:40888388
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;NS patients commonly show activation of the inflammatory axis, centered on IL-17 and IL-36, in the skin and blood, and show a psoriasis-like shift to Th17.&#34;
    explanation: This supports IL-17/IL-36 pathway activation as a measurable biochemical-inflammatory signature in NS.
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling.&#34;
    explanation: This supports conserved cytokine-axis upregulation across NS patients and mechanistic model systems.
genetic:
- name: SPINK5
  gene_term:
    preferred_term: SPINK5
    term:
      id: hgnc:15464
      label: SPINK5
  association: Causative
  notes: &gt;-
    Biallelic SPINK5 loss-of-function is causative, with variant location
    associated with phenotype severity in reported cohorts.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI.&#34;
    explanation: This directly supports SPINK5 as the causal gene and links genotype to LEKTI deficiency.
  - reference: PMID:27905021
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The identification of SPINK5, which encodes for the serine protease inhibitor LEKTI, as the gene responsible for Netherton syndrome, enabled the search for causative mutations in Netherton syndrome patients and families.&#34;
    explanation: This supports SPINK5 as the established disease gene and highlights genotype-phenotype analysis in affected families.
  - reference: PMID:39931731
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Among 162 patients, we identified 324 allele variants, comprising 75 different mutations.&#34;
    explanation: This supports broad allelic heterogeneity and the need for comprehensive SPINK5 variant interpretation.
  - reference: PMID:40159127
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G &gt; T, p.Trp825Cys).&#34;
    explanation: This supports ongoing expansion of pathogenic SPINK5 variant classes, including missense alleles.
  - reference: PMID:40969297
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS.&#34;
    explanation: This provides additional contemporary clinical evidence of SPINK5 defects as the diagnostic molecular basis of NS.
  - reference: PMID:36159989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We identified a novel frameshift mutation c.2474_2475del (p.Glu825Glyfs*2) in the SPINK5 gene.&#34;
    explanation: This adds evidence that novel SPINK5 pathogenic variants continue to be identified in NS.
diagnosis:
- name: SPINK5 molecular genetic testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: &gt;-
    Molecular testing of SPINK5 variants is central for confirming diagnosis and
    clarifying overlap with severe atopic dermatitis.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Due to the clinical overlap between NS and AD, we suggest performing SPINK5 genetic testing to search for the SPINK5 (NM_006846.4): c.1258A&gt;G polymorphism (rs2303067) and ensure a correct diagnosis, mainly in doubtful cases.&#34;
    explanation: This supports SPINK5 testing as a diagnostic discriminator in overlapping AD-like presentations.
  - reference: PMID:40969297
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS.&#34;
    explanation: This directly supports SPINK5 molecular confirmation in contemporary NS case diagnosis.
  - reference: PMID:40709761
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Additionally, 4 patients were diagnosed with syndromic ichthyosis, comprising 1 case of Chanarin-Dorfman syndrome and 3 cases of Netherton syndrome.&#34;
    explanation: This supports molecularly informed diagnostic workup in inherited ichthyosis cohorts that include NS cases.
  - reference: PMID:38406644
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Genetic testing of SPINK5 gene is key to confirming the diagnosis and starting early treatment.&#34;
    explanation: This directly supports SPINK5 testing as a key confirmatory diagnostic strategy.
- name: Skin biopsy with adjunct immunohistochemistry
  diagnosis_term:
    preferred_term: skin biopsy
    term:
      id: MAXO:0000423
      label: biopsy of skin
  description: &gt;-
    Histopathologic evaluation with adjunct IL-36 immunostaining can support
    diagnosis; LEKTI immunostaining alone may be insufficient in some cases.
  evidence:
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;LEKTI IHC was negative in one biopsy, revealing a limitation of this stain in diagnosing NS.&#34;
    explanation: This supports using broader biopsy-based immunohistochemical approaches rather than relying only on LEKTI IHC.
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Consequently, immunohistochemistry (IHC) with IL-36 may serve as a potential tool for aiding the histopathological diagnosis of this condition.&#34;
    explanation: This supports IL-36 IHC as a potential adjunct in histopathologic diagnosis.
differential_diagnoses:
- name: Atopic eczema
  disease_term:
    preferred_term: atopic eczema
    term:
      id: MONDO:0004980
      label: atopic eczema
  description: &gt;-
    Severe atopic eczema can clinically overlap with NS, especially early in
    life with eczematous inflammation and pruritus.
  distinguishing_features:
  - Hair shaft abnormalities and inherited ichthyosis features support Netherton syndrome over isolated atopic eczema.
  - Pathogenic SPINK5 variants and LEKTI pathway dysfunction support Netherton syndrome.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene.&#34;
    explanation: This provides direct evidence of diagnostic confusion between NS and severe atopic dermatitis.
  - reference: PMID:38601387
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;While eczema was included in our differential diagnoses, the patient&#39;s systemic symptoms, including failure to thrive, prompted our team to consider other diagnoses.&#34;
    explanation: This supports practical diagnostic overlap with eczema and the need to broaden differential assessment in severe infantile disease.
- name: Autosomal recessive congenital ichthyosis
  disease_term:
    preferred_term: autosomal recessive congenital ichthyosis
    term:
      id: MONDO:0017265
      label: autosomal recessive congenital ichthyosis
  description: &gt;-
    NS belongs to inherited ichthyosis disorders and may overlap clinically with
    other autosomal recessive congenital ichthyosis subtypes.
  distinguishing_features:
  - Hair shaft abnormalities and strong atopic/allergic predisposition are characteristic clues favoring Netherton syndrome.
  - SPINK5/LEKTI-associated protease dysregulation provides mechanistic specificity for Netherton syndrome.
  evidence:
  - reference: PMID:27905021
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system.&#34;
    explanation: This supports overlap within ARCI-like ichthyosis presentations while defining NS as a specific syndromic form.
- name: Chanarin-Dorfman syndrome
  disease_term:
    preferred_term: Dorfman-Chanarin disease
    term:
      id: MONDO:0010155
      label: Dorfman-Chanarin disease
  description: &gt;-
    Chanarin-Dorfman syndrome can overlap with syndromic ichthyosis
    presentations and requires molecular discrimination from Netherton syndrome.
  distinguishing_features:
  - Trichorrhexis invaginata with pathogenic SPINK5 variants supports Netherton syndrome over alternative syndromic ichthyoses.
  evidence:
  - reference: PMID:40709761
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Additionally, 4 patients were diagnosed with syndromic ichthyosis, comprising 1 case of Chanarin-Dorfman syndrome and 3 cases of Netherton syndrome.&#34;
    explanation: This supports real-world diagnostic overlap between NS and Chanarin-Dorfman syndrome in inherited ichthyosis cohorts.
- name: Psoriasis
  disease_term:
    preferred_term: psoriasis
    term:
      id: MONDO:0005083
      label: psoriasis
  description: &gt;-
    Chronic erythro-scaling inflammatory dermatoses such as psoriasis can mimic
    Netherton syndrome and delay diagnosis.
  distinguishing_features:
  - Hair shaft abnormalities with congenital onset and syndromic ichthyosis features support Netherton syndrome over psoriasis-spectrum diseases.
  evidence:
  - reference: PMID:38638763
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits.&#34;
    explanation: This directly supports real-world diagnostic confusion between NS and psoriasis.
- name: Pityriasis rubra pilaris
  disease_term:
    preferred_term: pityriasis rubra pilaris
    term:
      id: MONDO:0100017
      label: pityriasis rubra pilaris
  description: &gt;-
    Pityriasis rubra pilaris can present with erythroderma and scaling that
    overlap with Netherton syndrome.
  distinguishing_features:
  - Hair shaft abnormalities and congenital ichthyosis features support Netherton syndrome over pityriasis rubra pilaris.
  evidence:
  - reference: PMID:38638763
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits.&#34;
    explanation: This directly supports real-world diagnostic confusion between NS and pityriasis rubra pilaris.
treatments:
- name: Supportive topical skin care
  description: &gt;-
    Emollients and topical anti-inflammatory therapy remain baseline management
    for scaling and eczematous inflammation, though control is often incomplete.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: clinicaltrials:NCT04244006
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus.&#34;
    explanation: This trial summary supports current reliance on topical supportive care and its limitations.
- name: Ex vivo SPINK5 gene-corrected epidermal sheet grafting (investigational)
  description: &gt;-
    Phase I ex vivo lentiviral gene therapy strategy using autologous epidermal
    sheets generated from genetically modified skin stem cells to restore LEKTI
    in Netherton syndrome.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells.&#34;
    explanation: This supports an ex vivo lentiviral SPINK5 gene-correction strategy in NS.
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome.&#34;
    explanation: This supports autologous epidermal sheet grafting from genetically corrected skin stem cells as the investigational treatment approach.
- name: Cytokine-targeted systemic pharmacotherapy
  description: &gt;-
    Biologics and JAK inhibitors are emerging options in severe disease,
    targeting IL-4/IL-13, IL-17, IL-36, and JAK pathways.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
    - preferred_term: abrocitinib
      term:
        id: NCIT:C166985
        label: Abrocitinib
  evidence:
  - reference: PMID:40888388
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This review provides a comprehensive overview of the current clinical landscape and future directions of biologics (e.g., dupilumab, secukinumab, ustekinumab) and small-molecule therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib) in the treatment of NS.&#34;
    explanation: This supports use of cytokine-targeted and JAK-pathway therapies in severe NS.
  - reference: PMID:40888388
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Though evidence remains limited to case reports and small series, preliminary data suggest that cytokine-targeted interventions-particularly those inhibiting IL-4, IL-13, IL-17, IL-36, and JAK pathways-may offer tangible clinical benefits.&#34;
    explanation: This supports potential efficacy while acknowledging current evidence limits.
  - reference: PMID:40969297
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Both patients had swift and enduring enhancement of skin lesions during the follow-up period.&#34;
    explanation: This case series adds contemporary human evidence that biologic pathway targeting can improve NS skin disease.
- name: Immunoglobulin and biologic systemic therapy
  description: &gt;-
    Systematic review data indicate skin improvement in many reported cases with
    immunoglobulins and biologics.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: immunoglobulin
      term:
        id: NCIT:C572
        label: Immunoglobulin
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
  evidence:
  - reference: PMID:35464459
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Immunoglobulins (13/15 cases) and biologicals (18/21 cases) showed improvement of the skin.&#34;
    explanation: This supports observed skin benefit in aggregated case-based treatment evidence.
  - reference: PMID:38634098
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Under this therapy, his skin status, infectious exacerbations, and quality of life all improved.&#34;
    explanation: This provides additional pediatric case-level support for IVIG-centered systemic therapy.
- name: Intravenous immunoglobulin (IVIG) for infection-prone pediatric NS
  description: &gt;-
    High-dose IVIG has been used in children with recurrent skin/systemic
    infections and severe inflammatory skin disease, with reported improvement in
    skin status and infectious exacerbations.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: immunoglobulin
      term:
        id: NCIT:C572
        label: Immunoglobulin
  evidence:
  - reference: PMID:38634098
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;KEY CLINICAL MESSAGE: High-dose intravenous immunoglobulin exhibits great potential in the treatment of Netherton syndrome.&#34;
    explanation: This explicitly supports IVIG as a promising strategy in pediatric NS.
  - reference: PMID:40607310
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions.&#34;
    explanation: This supports IVIG use in infection-prone NS with severe recurrent admissions.
- name: Dupilumab (IL-4/IL-13 pathway inhibition)
  description: &gt;-
    Dupilumab has shown improvement in pruritus and inflammatory skin disease in
    pediatric and mixed-age NS case reports/series.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
  evidence:
  - reference: PMID:40607310
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;When he was 6 years old, dupilumab was added to reduce skin inflammation and improve skin barrier function before food reintroduction.&#34;
    explanation: This supports dupilumab targeting inflammatory and barrier manifestations in pediatric NS.
  - reference: PMID:40969297
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab.&#34;
    explanation: This supports real-world use of dupilumab across pediatric and young-adult NS cases.
  - reference: PMID:35327681
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash.&#34;
    explanation: This adds additional case-level evidence for dupilumab benefit on pruritus and inflammatory skin burden.
- name: Secukinumab (IL-17 pathway inhibition)
  description: &gt;-
    IL-17A blockade with secukinumab has shown clinical improvement in refractory
    NS in case-level evidence.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
  evidence:
  - reference: PMID:40299794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;After 2 injections, the patient&#39;s condition markedly improved and the effect after the last injection was maintained for 4-5 months.&#34;
    explanation: This supports clinically meaningful short-term and sustained response to secukinumab in refractory NS.
  - reference: PMID:40969297
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab.&#34;
    explanation: This supports secukinumab use as part of targeted biologic treatment strategies in NS.
- name: Abrocitinib (JAK1 inhibitor)
  description: &gt;-
    JAK1 inhibition with abrocitinib has shown symptomatic and severity
    improvements in case-level NS evidence.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: abrocitinib
      term:
        id: NCIT:C166985
        label: Abrocitinib
  evidence:
  - reference: PMID:40159127
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.&#34;
    explanation: This supports JAK1 inhibition as a promising targeted option in NS.
- name: Secukinumab and dupilumab combination (investigational/observational)
  description: &gt;-
    Combination IL-17A and IL-4/IL-13 blockade has been reported in severe
    pediatric NS cohorts.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
  evidence:
  - reference: clinicaltrials:NCT07151508
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.&#34;
    explanation: This supports real-world investigational use of combination biologic therapy in severe pediatric NS.
clinical_trials:
- name: NCT01545323
  phase: PHASE_I
  status: UNKNOWN
  description: &gt;-
    Phase I ex vivo lentiviral gene therapy trial evaluating autologous
    epidermal sheets generated from SPINK5-corrected skin stem cells in
    Netherton syndrome.
  target_phenotypes:
  - preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  - preferred_term: Erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The investigators have been developing a gene therapy approach to treat this disorder.&#34;
    explanation: This supports clinical investigation of a gene therapy approach for Netherton syndrome.
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome.&#34;
    explanation: This describes the autologous SPINK5-corrected epidermal sheet intervention evaluated in the study.
- name: NCT04244006
  phase: PHASE_II
  status: UNKNOWN
  description: &gt;-
    Registered as a phase 2/3 pilot randomized placebo-controlled trial of
    dupilumab for moderate-to-severe Netherton syndrome.
  target_phenotypes:
  - preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  - preferred_term: Erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: clinicaltrials:NCT04244006
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The expected consequences of this study are that a 16-week course of dupilumab will be more effective than placebo for the treatment of moderate to severe NS Dupilumab could therefore improve skin condition and quality of life.&#34;
    explanation: This supports ongoing/registered evaluation of dupilumab for clinically significant NS disease burden.
- name: NCT07151508
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: &gt;-
    Completed observational study describing combination secukinumab and
    dupilumab use in severe pediatric Netherton syndrome.
  target_phenotypes:
  - preferred_term: Atopic dermatitis
    term:
      id: HP:0001047
      label: Atopic dermatitis
  evidence:
  - reference: clinicaltrials:NCT07151508
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.&#34;
    explanation: This supports real-world evidence generation for combination biologic therapy in pediatric NS.
datasets:
- accession: geo:GSE224280
  title: Transcriptome profiling of lesional skin from Spink5 conditional knock-out mice
  description: &gt;-
    GEO transcriptome dataset from lesional skin in a viable Spink5 conditional
    knock-out Netherton syndrome mouse model.
  data_type: BULK_RNA_SEQ
  publication: DOI:10.1038/s42003-024-05780-y
  evidence:
  - reference: GEO:GSE224280
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;To characterize this model at the molecular level, we induced Spink5 deletion in young adult mice and collected lesional skin samples for transcriptome analyses.&#34;
    explanation: This supports transcriptomic dataset use for mechanistic profiling of Spink5-deficient skin.
- accession: geo:GSE224409
  title: Transcriptome profiling of lymph nodes from Spink5 conditional knock-out mice
  description: &gt;-
    GEO transcriptome dataset from inguinal lymph nodes in the Spink5
    conditional knock-out model to characterize systemic inflammation.
  data_type: BULK_RNA_SEQ
  publication: DOI:10.1038/s42003-024-05780-y
  evidence:
  - reference: GEO:GSE224409
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;To study the systemic inflammation phenotype of this mouse model at the molecular level, we induced Spink5 deletion in the skin of young adult mice and collected inguinal lymph nodes for transcriptome analyses.&#34;
    explanation: This supports transcriptomic profiling of lymphoid tissue to characterize systemic inflammatory mechanisms in NS models.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Netherton_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>